CClinicalTrials.gg
CompletedNCT05936203MARTA-walkUpdated Feb 22, 2024

Management of Prolonged Aerobic exeRcise in Patients With Type 1 Diabetes on Advanced Technologies

An interventional study of Insulin therapy adjustment and Nutritional adjustment in Type1diabetes, sponsored by Federico II University. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by Federico II University · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2023, registered Jun 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare three different therapeutic and nutritional approaches during a prolonged aerobic exercise in moderately active type 1 diabetes people using advanced technologies, to identify the best strategy for the management of this type of exercise. Participants will be randomly assigned to different interventions in three different occasions: insulin therapy adjustment; nutritional adjustment; combination of insulin and nutritional adjustment.

Read the detailed description

Regular exercise is recommended in people with type 1 diabetes (T1D) for its several health benefits (increased cardiovascular fitness, greater muscle strength, improved insulin sensitivity). However, therapeutic, and nutritional management of physical exercise is complex due to the multiple intra- and interindividual factors influencing glycemic response to exercise in T1D people. Glucose levels can increase, stay stable, or decrease depending on the type, duration, and intensity of exercise. During prolonged aerobic exercise, there is an increase in the risk of hypoglycemia also in patients using advanced technologies such as the hybrid artificial pancreas (HAP). The HAP consists of a continuous glucose monitoring (CGM) sensor and an insulin pump connected by a control algorithm that infuses insulin based on the glucose value recorded by the CGM sensor. With HAP there is the possibility to set a higher glucose target to make the insulin doses less aggressive during a scheduled session of physical exercise thus reducing the risk of hypoglycemia. However, there are different approaches, including insulin therapy adjustments or consumption of carbohydrates, proposed to minimize glycemic excursions during prolonged aerobic exercise in patients with T1D. Currently, the best strategy to manage physical exercise in people with type 1 diabetes on HAP, is not defined.

So, the aim of this study is to identify the optimal strategy for the management of prolonged aerobic exercise in moderately active T1D patients using hybrid artificial pancreas treatment. The exercise consists of an outdoor walk of 10 km over 4 hours and a height difference of 200-300 m. Each participant will be randomly assigned to three different therapeutic and nutritional interventions on three different occasions: 1)Target, which consists in setting a higher glucose target from 1 hour before until the end of the walk; 2) Snack, which consists of the consumption of 15 g of complex carbohydrates as whole grain crackers every 30 minutes, during the 4 hours of the walk; 3) Target+Snack consists in the combination of both Target and Snack interventions. Glycemic control expressed as CGM metrics and insulin doses delivered by HAP during the 4 hours of walks will be assessed.

02

Conditions studied

  • Type1diabetes

Keywords

  • prolonged aerobic exercise
  • hybrid artificial pancreas
  • carbohydrates supplementation
  • insulin therapy
03

In context

Diabetes Mellitus

10,923 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.

This study's enrollment of 18 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Federico II University is the lead sponsor of 356 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Type 1 diabetes
  • Using of hybrid artificial pancreas

Exclusion criteria

Exclusion Criteria:

  • Health conditions that may affect the safe performance of physical activity
  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Target

    Setting a higher glucose target starting from 1 hour before until the end of walk.

    Other: Insulin therapy adjustment

  • Experimental
    Snack

    Consumption of 15 g of complex carbohydrates as whole grain crackers every 30 minutes, during the 4 hours of walk.

    Other: Nutritional adjustment

  • Experimental
    Target + Snack

    Combination of both Target and Snack interventions.

    Other: Combination of strategies

Interventions

  • OtherInsulin therapy adjustment

    Strategies used to manage glucose control during a prolonged aerobic exercise

  • OtherNutritional adjustment

    Strategies used to manage glucose control during a prolonged aerobic exercise

  • OtherCombination of strategies

    Strategies used to manage glucose control during a prolonged aerobic exercise

06

What researchers measure

Primary outcomes

  1. Time in Range

    Glucose concentrations at 5-min intervals will be downloaded from dedicated platforms and the percentage of time with a glycemia between 70-180 mg/dl during 4 hours of walks will be derived.

    Time frame: During 4 hours of walks in 3 different occasions

  2. Insulin doses delivered

    Total insulin doses delivered by HAP during 4 hours of walks will be downloaded from the dedicated platforms.

    Time frame: During 4 hours of walks in 3 different occasions

07

Study locations

1 site
  • Federico II University Hospital
    Naples, 80131, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05936203
Lead sponsor
Federico II University
Responsible party
Giovanni Annuzzi (Professor, Medical Doctor, Federico II University) — Principal investigator
First posted
Jul 7, 2023
Start date
Jan 11, 2023
Primary completion
Feb 15, 2024
Completion
Feb 15, 2024
Last update
Feb 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion